[{"data":1,"prerenderedAt":152},["ShallowReactive",2],{"drug-bremelanotide":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":19,"regimens":34,"contraindications":56,"warnings":66,"renal":67,"monitoring":68,"interactions":69,"review":70,"examples":73,"atc":79,"iran":81,"links":88,"populations":104,"usApproval":147},"bremelanotide",1,{"fa":7,"en":8},"برملانوتید","Bremelanotide","genitourinary-sex-hormones",{"fa":11,"en":12},"آگونیست گیرنده ملانوکورتین","Melanocortin receptor agonist",[14],{"name":15,"market":16},"Vyleesi","US",[18,7],"vyleesi",[20],{"id":21,"form":22,"route":23,"label":24,"concentration":25,"markets":29,"refs":30},"pen","injection","sc","1.75 mg\u002F0.3 mL autoinjector",{"amount":26,"unit":27,"perUnit":28},1.75,"mg","application",[16],[31],{"source":32,"section":33},"fda-vyleesi","3",[35],{"id":36,"disease":36,"label":37,"population":40,"type":44,"unit":27,"dose":45,"refs":46,"notes":49},"hsdd",{"fa":38,"en":39},"کاهش میل جنسی زنان پیش از یائسگی — ۱٫۷۵ mg زیرجلدی دست‌کم ۴۵ دقیقه پیش از فعالیت","HSDD — 1.75 mg SC at least 45 min before activity",{"minAge":41},{"value":42,"unit":43},18,"year","fixed",{"perDose":26,"dosesPerDay":5},[47],{"source":32,"section":48},"2.1",[50],{"text":51,"refs":54},{"fa":52,"en":53},"بیش از یک دوز در ۲۴ ساعت نه؛ بیش از ۸ دوز در ماه توصیه نمی‌شود.","No more than one dose in 24 h; more than 8 doses per month not recommended.",[55],{"source":32,"section":48},[57],{"id":58,"severity":59,"text":60,"refs":63},"ci","block",{"fa":61,"en":62},"فشار خون کنترل‌نشده یا بیماری قلبی‌عروقی شناخته‌شده.","Uncontrolled hypertension or known cardiovascular disease.",[64],{"source":32,"section":65},"4",[],[],[],[],{"status":71,"reviewer":72,"date":72},"unverified",null,[74],{"regimen":36,"formulation":21,"input":75,"expect":78},{"ageYears":76,"weightKg":77},35,60,{"perDose":26},[80],"G02CX05",{"status":82,"refs":83},"not-found",[84],{"source":85,"section":86,"url":87},"darooyab-generic","search","https:\u002F\u002Fwww.darooyab.ir\u002FSearch?q=bremelanotide",[89,93,97,101],{"kind":90,"url":91,"label":92},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=210557","NDA210557",{"kind":94,"url":95,"label":96},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=f1d0c1b5-2f39-4bad-a6a4-0066e3ad5dcf","FDA Vyleesi",{"kind":98,"url":99,"label":100},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa619054.html","Bremelanotide Injection",{"kind":102,"url":103,"label":80},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G02CX05",{"pregnancy":105,"lactation":114,"pediatric":123,"geriatric":131,"reproductive":139},{"level":106,"text":107,"quote":110,"refs":111},"avoid",{"fa":108,"en":109},"برچسب: می‌تواند به جنین آسیب بزند. در بارداری خطرناک است.","Label: can cause fetal harm. Dangerous in pregnancy.","For this reason, women should use effective contraception while taking VYLEESI and discontinue VYLEESI if pregnancy is suspected.",[112],{"source":32,"section":113},"8.1",{"level":115,"text":116,"quote":119,"refs":120},"caution",{"fa":117,"en":118},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There is no information on the presence of bremelanotide or its metabolites in human milk, the effects on the breastfed infant, or the effects on milk production.",[121],{"source":32,"section":122},"8.2",{"level":115,"text":124,"quote":127,"refs":128},{"fa":125,"en":126},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness of VYLEESI have not been established in pediatric patients.",[129],{"source":32,"section":130},"8.4",{"level":115,"text":132,"quote":135,"refs":136},{"fa":133,"en":134},"برچسب: در سالمندان با احتیاط و معمولاً از دوز پایین شروع شود.","Label: use with caution in older adults, usually starting at the low end of the dose range.","The safety and effectiveness of VYLEESI have not been established in geriatric patients.",[137],{"source":32,"section":138},"8.5",{"level":115,"text":140,"quote":143,"refs":144},{"fa":141,"en":142},"برچسب نکته‌ای درباره بارداری، پیشگیری یا باروری زنان و مردان دارد.","Label has advice on pregnancy testing, contraception or fertility for females and males.","Contraception Use of VYLEESI during pregnancy is not recommended [see Use in Specific Populations ( 8.1 )].",[145],{"source":32,"section":146},"8.3",{"kind":148,"refs":149,"id":92},"NDA",[150],{"source":32,"section":151},"SPL approval \u002F marketing category",1792091053546]